Amneal Pharmaceuticals, Inc.

NasdaqGS:AMRX Rapport sur les actions

Capitalisation boursière : US$2.6b

Amneal Pharmaceuticals Gestion

Gestion contrôle des critères 4/4

Le PDG Amneal Pharmaceuticals est Chirag Patel, nommé en Jan2005, a un mandat de 19.83 ans. La rémunération annuelle totale est $ 2.37M, composée du salaire de 31.6% et des bonus 68.4%, y compris les actions et options de la société. détient directement 7.03% des actions de la société, d'une valeur de $ 181.23M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.3 ans et 6.5 ans.

Informations clés

Chirag Patel

Directeur général

US$2.4m

Rémunération totale

Pourcentage du salaire du PDG31.6%
Durée du mandat du directeur général19.8yrs
Propriété du PDG7.0%
Durée moyenne d'occupation des postes de direction5.3yrs
Durée moyenne du mandat des membres du conseil d'administration6.5yrs

Mises à jour récentes de la gestion

Recent updates

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Nov 10
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19
Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Dec 10

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Nov 28
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Sep 24

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Aug 08
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Amneal Pharmaceuticals Could Have An Upbeat Q2

Jul 10

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18
These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20
Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Nov 03

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Oct 28

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Aug 31

Analyse de la rémunération des PDG

Comment la rémunération de Chirag Patel a-t-elle évolué par rapport aux bénéfices de Amneal Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$184m

Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$169m

Dec 31 2023US$2mUS$750k

-US$84m

Sep 30 2023n/an/a

US$10m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

-US$135m

Dec 31 2022US$5mUS$750k

-US$130m

Sep 30 2022n/an/a

-US$132m

Jun 30 2022n/an/a

-US$134m

Mar 31 2022n/an/a

US$2m

Dec 31 2021US$5mUS$724k

US$11m

Sep 30 2021n/an/a

US$14m

Jun 30 2021n/an/a

US$9m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$2mUS$1

US$91m

Sep 30 2020n/an/a

US$62m

Jun 30 2020n/an/a

-US$194m

Mar 31 2020n/an/a

-US$199m

Dec 31 2019US$446kUS$44k

-US$362m

Sep 30 2019n/an/a

-US$339m

Jun 30 2019n/an/a

-US$67m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$325kn/a

-US$21m

Rémunération vs marché: La rémunération totale de Chirag ($USD 2.37M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 6.60M ).

Rémunération et revenus: La rémunération de Chirag a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Chirag Patel (57 yo)

19.8yrs

Titularisation

US$2,370,385

Compensation

Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Chirag Patel
Co-Founder19.8yrsUS$2.37m7.03%
$ 181.2m
Chintu Patel
Co-Founder22.8yrsUS$2.37m8.15%
$ 210.2m
Anastasios Konidaris
Executive VP & CFO4.7yrsUS$1.89m0.17%
$ 4.4m
Jason Daly
Senior VP2.8yrsUS$1.35m0.0044%
$ 113.7k
Nikita Shah
Executive VP & Chief Human Resources Officer10.8yrsUS$1.53m0.094%
$ 2.4m
Andrew Boyer
Executive VP & Chief Commercial Officer of Generics6.8yrsUS$1.94m0.083%
$ 2.1m
Anthony DiMeo
Head of Investor Relationsno datapas de donnéespas de données
Gregory Sgammato
Senior Vice President of Corporate Development1.8yrspas de donnéespas de données
Pranav Mehta
Senior VP of Strategic Sourcing & Supply Management1.8yrspas de donnéespas de données
Sanjay Jain
Chief Quality Officer5.8yrspas de donnéespas de données
Srinivas Kone
Senior VP & Chief Scientific Officer of Generics4.8yrspas de donnéespas de données
Stanley Fisher
Vice President & Head of Medical Affairsno datapas de donnéespas de données

5.3yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de AMRX est chevronnée et expérimentée (5.3 années d'ancienneté moyenne).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Chirag Patel
Co-Founder19.8yrsUS$2.37m7.03%
$ 181.2m
Chintu Patel
Co-Founder22.8yrsUS$2.37m8.15%
$ 210.2m
Paul Meister
Independent Chairman of the Board5.3yrsUS$299.08k0.23%
$ 6.1m
J. Buchi
Independent Director6.5yrsUS$302.20k0.085%
$ 2.2m
Ted Nark
Independent Director6.5yrsUS$244.70k0.097%
$ 2.5m
Shlomo Yanai
Independent Director4.9yrsUS$254.70k0.079%
$ 2.0m
Jeffrey George
Independent Director4.9yrsUS$277.20k0.087%
$ 2.2m
Gautam Patel
Director6.5yrsUS$217.20k0.66%
$ 17.0m
Deborah Autor
Independent Director2.3yrsUS$267.04k0.030%
$ 777.0k
Emily Alva
Independent Director6.5yrsUS$217.20k0.081%
$ 2.1m
John Kiely
Independent Director4.9yrsUS$284.70k0.083%
$ 2.1m

6.5yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AMRX sont considérés comme expérimentés (ancienneté moyenne 6.5 ans).